Source: International Congress 2017 – Cystic fibrosis: clinical issues
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
L. Boge (Hannover, Germany). Exploring the susceptibility of P. aeruginosa biofilms in human mucus towards tobramycin treatment. 1344

Member's Comments

No comment yet.

Related content which might interest you: Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro Source: Eur Respir J 2003; 21: 401-406 Year: 2003 The impact of testosterone on Pseudomonas aeruginosa pathogenicity and antimicrobial susceptibility Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018 Inhibitory activity of azithromycin on pseudomonas aeruginosa in biofilms Source: Eur Respir J 2003; 22: Suppl. 45, 450s Year: 2003 Effects of direct lung dosing of Tobramycin in a rat chronic infection model using Pseudomonas aeruginosa RP73 Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018 Azithromycin protects bronchial epithelial integrity after Pseudomonas aeruginosa infection independent of bactericidal activity Source: Annual Congress 2008 - Best of lung epithelial cells 2008 Year: 2008 Immunomodulatory properties of macrolide antibiotics in the treatment of bronchial sepsis involving P. aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 639s Year: 2004 Characterization of the resistance mechanisms to carbapenems and virulence genes in Pseudomonas aeruginosa strains from children with cystic fibrosis. Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021 Comparative in vitro activity of fluoroquinolones against P. aeruginosa isolated from Greek CF patients Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020 Effects of subinhibitory concentrations of antibiotics on the biofilm formation of pseudomonas aeruginosa Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011 Streptococcus pneumoniae inhibits Pseudomonas aeruginosa growth on nasal human epithelium in vitro Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 Antibiotic efficacy varies based on the infection model and treatment regimen for Pseudomonas aeruginosa Source: Eur Respir J, 55 (3) 1802456; 10.1183/13993003.02456-2018 Year: 2020 In vitro activity of colistin in combination with N-acetylcysteine against Pseudomonas aeruginosa Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research Year: 2018 Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 The role of efflux pump systems and OprD porine in antimicrobial resistance of Pseudomonas aeruginosa strains isolated from patients with bronchiectasis Source: Virtual Congress 2021 – Back to infection basics Year: 2021 Does Pseudomonas aeruginosa infection alter sputum viscoelastic properties in bronchiectasis patients? Source: International Congress 2018 – Chronic respiratory disease: respiratory muscle function, breathing exercises and airway clearance techniques Year: 2018 The effect of erythromycin on the chronic lower airway infection by pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004 Macrolide resistance in Pseudomonas aeruginosa: implications for practice Source: Eur Respir J, 49 (5) 1700689; 10.1183/13993003.00689-2017 Year: 2017 Biofilm production and adherence to airway epithelial cells of P. aeruginosa strains: effect of N-acetyl-cysteine Source: Eur Respir J 2005; 26: Suppl. 49, 726s Year: 2005 Human airway epithelial cell response to Pseudomonas aeruginosa virulence factors preceded or not by Staphylococcus aureus Source: Eur Respir J 2006; 28: Suppl. 50, 191s Year: 2006 Synergistic activity of colistin in combination with N-acetylcysteine against colistin-resistant Acinetobacter Baumannii grown in biofilms Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018